Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 7/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17997113 | 0.92 | SLC22A2 (0.57) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL16615621 | 0.88 | SLC22A2 (0.54) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22640360 | 0.88 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL22640370 | 0.86 | SLC22A2 (0.52) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19763318 | 0.83 | SLC22A2 (0.65) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL17997178 | 0.83 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL19824663 | 0.83 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL16615573 | 0.83 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL16615693 | 0.83 | SLC22A2 (0.53) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL16615509 | 0.83 | SLC22A2 (0.62) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9861620-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-08-11 | — | — | US | disclosed |
| WO-2015048363-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228419-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | NQO2, CYP3A5, QTRT1 | SLC22A2 1836/4885CYP3A4 27/4885TMEM97 3425/4885 |
| US-20180028509-A1 | SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS | NQO2, CYP3A5, QTRT1 | SLC22A2 1836/4885CYP3A4 27/4885TMEM97 3425/4885 |
| US-10201533-B2 | Substituted quinolizine derivatives useful as HIV integrase inhibitors | NQO2, CYP3A5, QTRT1 | SLC22A2 1836/4885CYP3A4 27/4885TMEM97 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.